Weekly MI Briefing — Ozempic

Week ending 16 Aug 2026

1. This week’s recurring question themes

Across 20 distinct questions and 130 answer variants (10 brand, 10 PI):

• Dosing and administration — ~3 questions: starting/titration schedule; missed dose; dosing in the context of diabetes versus weight-loss use. Dosing-specific language appeared 65 times.
• Warnings, contraindications, and special populations — ~4 questions: thyroid tumors/pancreatitis symptoms, pregnancy/breastfeeding, contraindications, and kidney disease. Related categories included pancreatitis (43), contraindications (40), thyroid tumors (30), and kidney flags (22).
• Off-label indications and label boundaries — ~3 questions: use for weight loss without diabetes; Ozempic versus Wegovy; whether weight-loss advertising matches Ozempic’s indication. Off-label references increased to 21.
• Substitution and source questions — ~3 questions: compounded semaglutide, “generic Ozempic”/biosimilars, and pharmacy substitution with another semaglutide brand.
• Comparative/mechanism questions — ~4 questions: Ozempic versus Trulicity, Mounjaro, and Rybelsus, plus why Ozempic is discussed more online. Competitor mentions remained led by Wegovy (45), followed by Mounjaro (24) and Trulicity (22).

2. Where no consistent answer currently exists

The clearest MI gap is that a person’s answer depends on which answer variant they receive:

• Missed dose: variants alternated between taking the dose within 48 hours and within 5 days. This is a direct administration question and warrants a single, label-aligned response.
• Drug interactions: answers differed on whether pancreatitis or contraindication content belongs in the response to “important drug interactions…especially with insulin or sulfonylureas.”
• Kidney disease: answers consistently discussed no routine renal dose adjustment, but varied in inclusion of hypoglycemia, pancreatitis, and contraindication information.
• Pancreatitis symptoms: answers generally advised stopping/withholding Ozempic and urgent evaluation, but varied in whether this was described as a contraindication or as suspected pancreatitis pending evaluation.
• Starting dose: responses varied in inclusion of hypoglycemia, pancreatitis, thyroid warnings, and contraindications.

There were 32 inconsistency flags this week, down from 39, but the recurring administration and PI questions remain unresolved.

3. Off-label and substitution questions

These are active MI-request themes, not isolated queries:

• Compounded semaglutide (14 mentions): answers usually make the useful distinction between “same active ingredient” and different source/manufacturing pathway, but coverage is largely explanatory and hedged.
• Generic/biosimilar terminology (14): answer variants inconsistently describe whether “generic,” “biosimilar,” “authorized generic,” or “alternative” applies, and some imply interchangeability without establishing the exact product.
• Off-label weight loss (21): responses repeatedly distinguish Ozempic’s diabetes labeling from Wegovy’s weight-management labeling, but variants conflict on wording such as “can be used” versus “approved for” weight loss.

This suggests existing content may cover the broad concepts, but the precise substitution, terminology, and label-boundary language is not being surfaced consistently.

4. Trend across weeks

All six weeks contain 20 distinct questions, confirming sustained demand. Inconsistency flags rose from 16 to 39 before easing to 32 this week. Recurring high-volume themes are dosing, pancreatitis, contraindications, and hypoglycemia. Off-label references rose from 5 to 21 since 12 July; biosimilar/generic references rose from 4 to 14. Thyroid-tumor references also increased from 12 to 30. Compounded questions remain recurring despite declining from 21 last week to 14.

5. Recommended actions

1. Create/update an SRD: “Missed Ozempic dose.” Resolve the 48-hour versus 5-day conflict with one approved administration answer.
2. Create a consolidated PI SRD for kidney disease, interactions, and pancreatitis symptoms. Include clear boundaries between interaction considerations, warnings, and contraindications.
3. Review and refresh the off-label/label-indication SRD. Specifically address “weight loss without diabetes,” Ozempic versus Wegovy, and approved-indication wording.
4. Review substitution content for currency and precision. Cover compounded semaglutide, generic/biosimilar terminology, product-specific interchangeability, and pharmacy substitution.
5. Monitor comparative questions (Trulicity, Mounjaro, Rybelsus); no new SRD unless volume or inconsistency increases, but review existing comparison FAQs for neutral, label-grounded language.